Skip to search boxSkip to navigationSkip to main content

Lysyl oxidase is a key player in BRAF/MAPK pathway-driven thyroid cancer aggressiveness

  • Myriem Boufraqech
    ,
  • Dhaval Patel
    ,
  • Naris Nilubol
    ,
  • Astin Powers
    ,
  • Timothy King
    ,
  • Jasmine Shell
*Corresponding author for this work
  • National Institutes of Health
    ,
  • Leidos Inc
    ,
  • Massachusetts General Hospital
    ,
  • Memorial Sloan-Kettering Cancer Center
    ,
  • Stanford University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p> Background: The BRAF <sup>V600E</sup> mutation is the most common somatic mutation in thyroid cancer. The mechanism associated with BRAF-mutant tumor aggressiveness remains unclear. Lysyl oxidase (LOX) is highly expressed in aggressive thyroid cancers, and involved in cancer metastasis. The objective was to determine whether LOX mediates the effect of the activated MAPK pathway in thyroid cancer. Methods: The prognostic value of LOX and its association with mutated BRAF was analyzed in The Cancer Genome Atlas and an independent cohort. Inhibition of mutant BRAF and the MAPK pathway, and overexpression of mutant BRAF and mouse models of BRAF <sup>V600E</sup> were used to test the effect on LOX expression. Results: In The Cancer Genome Atlas cohort, LOX expression was higher in BRAF-mutant tumors compared to wild-type tumors (p < 0.0001). Patients with BRAF-mutant tumors with high LOX expression had a shorter disease-free survival (p = 0.03) compared to patients with a BRAF mutation and the low LOX group. In the independent cohort, a significant positive correlation between LOX and percentage of BRAF mutated cells was found. The independent cohort confirmed high LOX expression to be associated with a shorter disease-free survival (p = 0.01). Inhibition of BRAF <sup>V600E</sup> and MEK decreased LOX expression. Conversely, overexpression of mutant BRAF increased LOX expression. The mice with thyroid-specific expression of BRAF <sup>V600E</sup> showed strong LOX and p-ERK expression in tumor tissue. Inhibition of BRAF <sup>V600E</sup> in transgenic and orthotopic mouse models significantly reduced the tumor burden as well as LOX and p-ERK expression. Conclusions: The data suggest that BRAF <sup>V600E</sup> tumors with high LOX expression are associated with more aggressive disease. The biological underpinnings of the clinical findings were confirmed by showing that BRAF and the MAPK pathway regulate LOX expression.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 79-92 (14 pages)

Journal (Volume, Issue Number)

Thyroid (Volume 29, Issue 1)

Publication milestones

  • Published - 01/2019

Publication status

Published - 01/2019

ISSN

1050-7256

Publication IDs

  • Scopus: 85060400382
  • PubMed: 30398411

Publication metrics

Metrics

Fractional count
1
Fractional count
0.06
Fractional count
17
Fractional count
0.94
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
26
Citation count
26

Funding Details

We would like to thank Dr. Carmelo Nucera for providing mouse samples. This research was supported by the intramural research program of the Center for Cancer Research, NCI, NIH (grant number 1ZIABC011275-06 to E.K.).
FundersFunding numbers
NIH
1ZIABC011275-06
NCI
-
NIDDK
ZIADK075139